NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-OD-18-166 from the NIH Guide for Grants and Contracts
Notice NOT-OD-18-157 from the NIH Guide for Grants and Contracts
Notice NOT-OD-18-163 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AI-18-010 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to determine how immunity, generated by the initial and subsequent influenza infections and/or vaccinations, shapes protective immunity to future influenza exposures in longitudinal human infant cohorts to help inform the design of durable, broadly protective influenza vaccines.
Funding Opportunity RFA-AR-19-006 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications that propose to conduct time-sensitive mechanistic ancillary studies related to the NIAMS mission in conjunction with privately or publicly funded, ongoing clinical projects. The ongoing parent clinical project can be an interventional clinical trial, or a clinical study such as an observational study that will be actively collecting patient samples or clinical data. The parent project(s) should provide a cohort of well-characterized patients, infrastructure, data, and biological samples for the ancillary study. Applications submitted in response to this FOA will undergo an accelerated review and award process. The objective of this FOA is to provide a flexible mechanism to leverage established resources and maximize the return on existing investments in parent projects. Successful ancillary studies will enhance the scientific content and value of the parent projects, improve the research communitys understanding of a disease or organ system in the NIAMS portfolio, and thus may identify novel targets for diagnosis, treatment, and prevention of disease.
Funding Opportunity RFA-AR-19-007 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications that propose to conduct time-sensitive mechanistic ancillary studies related to the NIAMS mission in conjunction with privately or publicly funded, ongoing clinical projects. The ongoing parent clinical project can be an interventional clinical trial, or a clinical study such as an observational study that will be actively collecting patient samples or clinical data. The parent project(s) should provide a cohort of well-characterized patients, infrastructure, data, and biological samples for the ancillary study. Applications submitted in response to this FOA will undergo an accelerated review and award process. The objective of this FOA is to provide a flexible mechanism to leverage established resources and maximize the return on existing investments in parent projects. Successful ancillary studies will enhance the scientific content and value of the parent projects, improve the research communitys understanding of a disease or organ system in the NIAMS portfolio, and thus may identify novel targets for diagnosis, treatment, and prevention of disease.
Funding Opportunity PAR-18-743 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is to support Exploratory/Developmental Research Grants (R21) that propose small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to urologic disorders research. Studies should address important clinical and translational questions that are potentially of high clinical and public health impact. It is anticipated that some projects supported by these grants may lead to full-scale clinical studies including diagnostic strategies, epidemiological studies, or randomized clinical trials of prevention, diagnosis or treatment of urologic disorders.
Funding Opportunity PAR-18-744 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is to support Exploratory/Developmental Research Grants (R21) that propose small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to kidney disease research. Studies should address important clinical and translational questions and are potentially of high clinical and public health impact. It is anticipated that some projects supported by these grants may lead to full-scale clinical studies including diagnostic strategies, epidemiological studies, or randomized clinical trials of diagnosis, prevention, or treatment of kidney diseases.
Funding Opportunity RFA-CA-18-021 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites revision applications from investigators with active NCI R01 research grants. These revision applications are expected to focus on research related to one of the 12 of the NCI's Provocative Questions (PQs) published for new applications in RFA-CA-18-019 (R01) and RFA-CA-18-020 (R21) . This FOA encourages research that directly addresses PQs, including research that helps validate PQ research outcomes or adopt and disseminate PQ research results that impact cancer research and clinical care. Studies proposed in the revision applications must correspond to additional specific aims, expanding the scope of individual, already funded projects of the parent R01 award.
Funding Opportunity RFA-CA-18-022 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites revision applications from investigators with active NCI U01 research grants. These revision applications are expected to focus on research related to one of the 12 of the NCI's Provocative Questions (PQs) published for new applications in RFA-CA-18-019 (R01) and RFA-CA-18-020 (R21) . This FOA encourages research that directly addresses PQs, including research that helps validate PQ research outcomes or adopt and disseminate PQ research results that impact cancer research and clinical care. Studies proposed in the revision applications must correspond to additional specific aims, expanding the scope of individual, already funded projects of the parent U01 award.
Funding Opportunity RFA-CA-18-024 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites revision applications from investigators with active NCI P50 research grants. These revision applications are expected to focus on research related to one of the 12 of the NCI's Provocative Questions (PQs) published for new applications in RFA-CA-18-019 (R01) and RFA-CA-18-020 (R21) . This FOA encourages research that directly addresses PQs, including research that helps validate PQ research outcomes or adopt and disseminate PQ research results that impact cancer research and clinical care. Studies proposed in the revision applications must correspond to additional specific aims, expanding the scope of individual, already funded projects of the parent P50 award.
Funding Opportunity RFA-CA-18-023 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites revision applications from investigators with active NCI P01 research grants. These revision applications are expected to focus on research related to one of the 12 of the NCI's Provocative Questions (PQs) published for new applications in RFA-CA-18-019 (R01) and RFA-CA-18-020 (R21) . This FOA encourages research that directly addresses PQs, including research that helps validate PQ research outcomes or adopt and disseminate PQ research results that impact cancer research and clinical care. Studies proposed in the revision applications must correspond to additional specific aims, expanding the scope of individual, already funded projects of the parent P01 award.
Notice NOT-CA-18-060 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-18-742 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to encourage research that investigates the role of molecular epigenetic or non-coding RNA regulatory pathways in the development or maintenance of chronic pain. Ultimately research in the area will provide foundational knowledge that can be exploited to develop novel and non-addictive pain medications.
Funding Opportunity PA-18-741 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushings diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and nutrition; kidney, urologic, and hematologic diseases. The goal of this program is to facilitate research that explores innovative hypotheses through the use of existing data sets or data, for which the primary goal is data analysis and not preparation/presentation of data.
Funding Opportunity RFA-RM-18-011 from the NIH Guide for Grants and Contracts. The overarching goal of this FOA is to add informatics capabilities to the Common Fund program, Illuminating the Druggable Genome (IDG; https://commonfund.nih.gov/idg/index). The IDG consortium's purpose is to facilitate the unveiling of the functions of selected understudied proteins in the Druggable Genome using experimental and informatics approaches. Currently, this research consortium is composed of multiple Data and Resource Generation Centers (DRGCs), a Knowledge Management Center (KMC), and a Resource Dissemination and Outreach Center (RDOC). The purpose of this specific FOA is to solicit applications to build a set of Cutting Edge Informatics Tools (CEITs) that will augment the capability of the KMC as well as the broader IDG Consortium in two ways: (1) by deploying tools to enhance the communitys ability to process, analyze, visualize data, to prioritize new data resources and methods to be incorporated into Pharos that will strengthen predictions about physiological and disease associations around the understudied proteins and (2) to prioritize physiological and disease relevant cellular and animal models for further study of the understudied proteins (non-olfactory GPCRs, protein kinases, and ion channels) both within the IDG program and by the larger community.
Funding Opportunity PAR-18-740 from the NIH Guide for Grants and Contracts. This FOA encourages applications for the Lasker Clinical Research Scholars Program for the purpose of supporting the research activities during the early stage careers of independent clinical researchers. The program offers the opportunity for a unique bridge between the NIH intramural and extramural research communities and contains two phases. In the first phase, Lasker scholars will receive appointments for up to 5-7 years as tenure-track investigators within the NIH Intramural Research Program with independent research budgets. In the second phase, successful scholars will receive up to 3 years of NIH support for their research at an extramural research facility; or, the scholar can be considered to remain as an investigator within the intramural program
Funding Opportunity PA-18-738 from the NIH Guide for Grants and Contracts. The overall purpose of this funding opportunity announcement (FOA) is to assess the role of the microbiome in health and disease during aging. This initiative will support research projects designed to evaluate changes in the microbiota during lifetime and its influence in health and disease status in the elderly, including those from racial/ethnic minority and underserved populations and understand the underlying mechanisms of microbiota interactions in aged subjects as related to health and disease. This FOA will accept basic mechanistic, preclinical studies in animal models and human clinical trial proposals in accordance with the state of the science.
Funding Opportunity PA-18-739 from the NIH Guide for Grants and Contracts. The overall purpose of this funding opportunity announcement (FOA) is to assess the role of the microbiome in health and disease during aging. This initiative will support research projects designed to evaluate changes in the microbiota during lifetime and its influence in health and disease status in the elderly, including those from racial/ethnic minority and underserved populations and understand the underlying mechanisms of microbiota interactions in aged subjects as related to health and disease. This FOA will accept basic mechanistic, preclinical studies in animal models and human clinical trial proposals in accordance with the state of the science.
Notice NOT-CA-18-056 from the NIH Guide for Grants and Contracts